Guidance document on bevacizumab compounding and endophthalmitis risk mitigation

The Academy has developed a document, Verifying the Source of Compounded Bevacizumab for Intravitreal Injection, to help address issues related to the compounding of bevacizumab and recent infection clusters. The Academy recommends selecting a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board and adherent to quality standards for aseptic compounding of sterile medications. The document also provides links to relevant risk management guidance from Ophthalmic Medical Insurance Company (OMIC) and articles in the literature on antisepsis and antimicrobial prophylaxis for intravitreal injections.